# Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan

> **NCT06052800** · — · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 78 (actual)

## Conditions studied

- Fabry Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06052800
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-13
- **Primary completion:** 2026-09-10
- **Final completion:** 2026-09-10
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2026-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06052800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06052800, "Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan". Retrieved via AI Analytics 2026-09-17 from https://api.ai-analytics.org/clinical/NCT06052800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*